polythiazide

Trade name: renese

Small moleculeapproved

Approved

Sep 26, 1961

Polythiazide is a thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. Polythiazide under brand name Rense is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. The mechanism of action results in an interference with the renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage, all thiazides are approximately equal in their diuretic potency. The mechanism whereby thiazides function in the control of hypertension is unknown, but as a diuretic, polythiazide inhibits active chloride reabsorption at the early distal tubule via the thiazide-sensitive Na-Cl cotransporter (TSC), resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like polythiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of polythiazide may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1960s

  1. Sep 26, 1961

    Pfizer — Earliest FDA Approval

  2. Sep 26, 1961

    Pfizer — NDA Organization

Indications

Mechanism of action

Combination products

Approval history

  • approvedSep 26, 1961

Chemistry & pharmacology

Loading structure…

SMILES

CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O
Mol. weight
439.882 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • drenusil
  • nephril
  • nephril
  • nephril
  • p-2525
  • p-2525
  • polythiazide
  • polythiazide
  • polythiazide
  • polythiazide
  • polythiazide
  • polythiazide
  • polythiazide
  • polythiazide
  • polythiazide
  • polythiazide
  • renese
  • renese
  • renese
  • renese
  • renese
  • renese
  • renese

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
PfizerFor profitSYNSep 26, 1961
PfizerFor profitNDASep 26, 1961